Botanical

Shilapuspha

Didymocarpus pedicellata

Shilapuspha (Didymocarpus pedicellata) is a plant tested as one ingredient of Cystone, an Ayurvedic nine-ingredient tablet marketed for kidney stones. In a small placebo-controlled crossover study with a year of open-label follow-up, the tablet did not change urinary stone chemistry and average stone burden rose slightly, so no benefit can be assigned to this herb; it has not been tested on its own.

1

STUDY

6

STUDIED WITH

1

CONDITIONS

3

TRADITIONS

Studies about Shilapuspha in Akasha →

How it's used

Parts and preparations, and the conditions they're used for.

not specified · component of Cystone polyherbal tablet (Himalaya)Kidney Stones

These uses are flagged for review — traditional-use claims kept as reported, never as advice.

What the studies found

Findings backed by a source paper, not traditional use alone.

not specified · component of Cystone polyherbal tablet (Himalaya) — Tested only within the nine-ingredient Cystone formulation (n=10 recurrent calcium oxalate stone formers): no significant effect on urinary supersaturation at 6 or 52 weeks; mean stone burden per kidney rose (volumetric 93 to 114 mm3, P=0.07; Agatston 108 to 136 AU, P=0.10). Not attributable to this component.

Read the source study →

Studies about Shilapuspha

1 completed study · newest first

Effect of Cystone® on urinary composition and stone formation over a one year period.

S B Erickson et al. (2011) · Phytomedicine : international journal of phytotherapy and phytopharmacology

This small randomized trial with 10 people explored whether Cystone, an Ayurvedic herbal tablet sold for kidney stones, changes the urine chemistry that drives stone formation or reduces the amount of stone in the kidneys. Kidney stones are painful and often recur, and the available prevention options (diet changes and medicines such as thiazides, potassium citrate and allopurinol) have drawbacks. Cystone is a blend of seven plants plus purified Shilajeet and a mineral preparation (bhasma), traditionally used for urinary problems, but the authors say earlier studies of it were small and poorly controlled. Ten adults from the Mayo Stone Clinic who repeatedly formed calcium oxalate stones took two Cystone tablets twice a day, or matching placebo, for six weeks each in a crossover design, switching after a one-week break. All then took Cystone openly for another 48 weeks. Urine collected over 24 hours measured how saturated it was with stone-forming minerals. CT scans at the start and after a year, scored with the same method used for heart-artery calcium, measured stone volume, and a radiologist reviewed them without knowing the timing. Cystone did not change urinary measurements in the short term (6 weeks) or the long term (52 weeks). Average stone burden per kidney actually rose from 93 to 114 cubic millimetres (P = 0.07) and from 108 to 136 on the Agatston scale (P = 0.10), neither statistically significant. The radiologist counted 8 kidneys with more stone, 8 unchanged and 2 with less, and four kidneys passed stones spontaneously. No participant described side effects they attributed to Cystone. The authors conclude the trial does not support Cystone for preventing calcium oxalate stones, while noting the sample was tiny, participants had stones that standard treatment had not controlled, and some factors that inhibit stone formation were not measured. They say a longer study with more patients would be needed to look at stone passage or other stone types.

Read summary →Full text available